Depressive Disorders
Depressive disorders, particularly major depressive disorder (MDD), are significant contributors to global mental health issues. Research into the therapeutic potential of psychedelics, such as psilocybin and ketamine, offers promising avenues for treatment, especially for cases that are resistant to conventional therapies.
What is Depressive Disorders?
Depression, also known as major depressive disorder (MDD), is characterised by persistent feelings of sadness, lack of interest in previously enjoyed activities, and various physical symptoms such as disrupted sleep and appetite.
The DSM-V outlines key symptoms, which include: depressed mood, diminished interest, feelings of worthlessness, recurrent suicidal thoughts, and fatigue. To receive a diagnosis, a patient must exhibit at least five of these symptoms over a two-week period.
The pathophysiology of depression remains complex and contentious, with several proposed mechanisms, including the monoamine hypothesis, but no definitive consensus.
Common tools for diagnosis include the Hamilton Depression Rating Scale (HDRS), the Patient Health Questionnaire (PHQ-9), and the Beck Depression Inventory (BDI).
Depression is prevalent globally, affecting approximately 260 million individuals, and remains one of the leading causes of years lived with disability.
Current Treatments
Current standard-of-care treatments for depression include various psychotherapeutic approaches (e.g., cognitive behavioural therapy) alongside antidepressant medications such as SSRIs, SNRIs, TCAs, and MAOIs. However, these treatments often have delayed onset of effect and may carry significant side effects.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for Depressive Disorders.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Esketamine Esketamine has demonstrated strong efficacy in multiple phase III trials for treatment-resistant depression. | Large | High | Consistent |
| Psilocybin Psilocybin has shown significant results in reducing depressive symptoms in various studies, featuring a durable effect over time. | Medium | Moderate | Consistent |
| LSD The historical context impedes modern research, but preliminary studies suggest potential benefits. | Medium | Low | Inconsistent |
| Ayahuasca Existing studies indicate significant improvement in depression symptoms, although further controlled trials are needed. | Medium | Moderate | Consistent |
| Ketamine Numerous studies confirm the rapid antidepressant effects of ketamine, especially in acute cases. | Large | High | Highly Consistent |
Esketamine and Depressive Disorders
Esketamine binds to NMDA receptors and modulates synaptic transmission, leading to increased glutamate levels in the brain. This action promotes synaptogenesis and can result in immediate reduction of depressive symptoms, particularly beneficial for individuals exhibiting active suicidal ideation. Esketamine's unique dissociative properties provide a rapid response that contrasts with conventional antidepressants.
Psilocybin and Depressive Disorders
Psilocybin appears to act as a serotonin receptor agonist, primarily affecting the 5HT2A receptors, and leads to alterations in neural connectivity, particularly within the default mode network (DMN). This transformation may foster psychological flexibility and reduce entrenched negative thought patterns, contributing to its efficacy in alleviating symptoms of depression over an extended period.
Ketamine and Depressive Disorders
As a dissociative anaesthetic, ketamine induces a state that alters perception and can facilitate the examination and reshaping of deep-rooted cognitive patterns. Its therapeutic mechanism involves blockage of NMDA receptors while promoting AMPA receptor activation, increasing levels of brain-derived neurotrophic factor (BDNF), and leading to rapid alleviation of depressive symptoms, particularly in treatment-resistant patients.
Ayahuasca and Depressive Disorders
Ayahuasca has been linked to significant mood improvements potentially through modulation of neurotrophic factors and anti-inflammatory pathways. The experience often precipitates introspection and emotional processing, which can help individuals confront and transcend underlying issues contributing to their depression. Studies suggest its antidepressant effects are sustained, providing lasting benefits well beyond the acute treatment period.
LSD and Depressive Disorders
Research has indicated that LSD can lead to profound alterations in consciousness and self-perception, which may assist in resolving issues related to depressive thought patterns. Its effects on brain connectivity can facilitate psychological exploration, thereby enabling patients to confront and re-evaluate negative beliefs that contribute to depression.
Key Insights
- 1
The FDA has granted breakthrough therapy status to psychedelics like esketamine and psilocybin for treatment-resistant depression (TRD), highlighting their clinical potential.
- 2
Ketamine is known for its rapid antidepressant effects, particularly beneficial for patients with acute suicidal ideation.
- 3
Psychedelics can induce lasting changes in mood and cognition, with evidence showing significant reductions in depressive symptoms following just one or two sessions.
- 4
Ayahuasca has been associated with considerable mental health improvements, including self-reported reductions in depressive symptoms among participants at retreats.
- 5
Research indicates that psychedelics may help reset dysfunctional thought patterns by affecting brain regions associated with self-concept and emotional processing.
Industrial Landscape
Key players in this area include COMPASS Pathways, which is developing psilocybin therapy; Johnson & Johnson, responsible for bringing esketamine to market; and several research institutions such as Johns Hopkins University and Imperial College London, which are conducting pivotal studies on the applications of psychedelics in treating depression.
Quick Indicators
\"Ongoing clinical evaluations are investigating Depressive Disorders as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with Depressive Disorders.